Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Literature Review of Racial Disparities in Prostate Cancer Research.
Vermeille M, Koster KL, Benzaquen D, Champion A, Taussky D, Kaulanjan K, Früh M. Vermeille M, et al. Among authors: fruh m. Curr Oncol. 2023 Nov 12;30(11):9886-9894. doi: 10.3390/curroncol30110718. Curr Oncol. 2023. PMID: 37999138 Free PMC article. Review.
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma.
Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau JF, Jean D, Felley-Bosco E. Sun S, et al. Among authors: fruh m. JTO Clin Res Rep. 2022 Nov 7;3(12):100430. doi: 10.1016/j.jtocrr.2022.100430. eCollection 2022 Dec. JTO Clin Res Rep. 2022. PMID: 36467966 Free PMC article.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: fruh m. Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34839016 Free article. Clinical Trial.
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Wyss N, Berner F, Walter V, Jochum AK, Purde MT, Abdou MT, Sinnberg T, Hofmeister K, Pop OT, Hasan Ali O, Bauer J, Cheng HW, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer BS, Driessen C, Schürch CM, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy AN, Schneider T, Brutsche MH, Sette A, Lenz TL, Walz J, Rammensee HG, Früh M, Jäger E, Becher B, Tufman A, Nuñez N, Joerger M, Flatz L. Wyss N, et al. Among authors: fruh m. Am J Respir Crit Care Med. 2024 Apr 16. doi: 10.1164/rccm.202311-2136OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 38626354
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi K, Maranta AF, Bastian S, von Moos R, Joerger M, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Mark M, et al. Among authors: fruh m. Eur J Cancer. 2024 Mar;200:113600. doi: 10.1016/j.ejca.2024.113600. Epub 2024 Feb 5. Eur J Cancer. 2024. PMID: 38330766 Free article. Clinical Trial.
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark MT, Rothschild SI, Addeo A, Janthur WD, Siano M, Boos L, Britschgi C, Früh M. Schuler A, et al. Among authors: fruh m. Lung Cancer. 2024 Jan;187:107427. doi: 10.1016/j.lungcan.2023.107427. Epub 2023 Nov 22. Lung Cancer. 2024. PMID: 38043395
Non-pharmaceutical interventions to optimize cancer immunotherapy.
Boesch M, Baty F, Rassouli F, Kowatsch T, Joerger M, Früh M, Brutsche MH. Boesch M, et al. Among authors: fruh m. Oncoimmunology. 2023 Sep 28;12(1):2255459. doi: 10.1080/2162402X.2023.2255459. eCollection 2023. Oncoimmunology. 2023. PMID: 37791231 Free PMC article. Review.
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Opitz I, Guckenberger M, Früh M, Betticher DC, Ris HB, Stupp R, Rothschild SI, Bubendorf L, Pless M. König D, et al. Among authors: fruh m. ESMO Open. 2023 Aug;8(4):101595. doi: 10.1016/j.esmoop.2023.101595. Epub 2023 Jul 11. ESMO Open. 2023. PMID: 37441877 Free PMC article.
134 results